Meta-analysis from these studies showed higher mean platelet count among adult ITP patients who were given SYK and/or BTK inhibitors than those who only received placebo (Mean Difference 48.35 × 109/L; 95%CI: 37.71 – 58.98, p<0.00001, I2 = 47%, random-effect model) (Figure 2C) (Table 3). Here, SYK is linked to autoimmune thrombocytopenic purpura.